Funded by U.S. Department of Defense, Published in Case Report
CAMBRIDGE, Mass. (July 6, 2020) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that new published research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “Despite long-standing traumatic brain injury, meaningful improvements in motor function were observed.” Read more.